Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
HS disease duration of at least 3 months before screening.
Willingness to avoid pregnancy or fathering children.
Active HS in at least 2 distinct anatomical areas.
Participants agree NOT to use topical antiseptics on the areas affected by HS lesions during the placebo-controlled 16-week treatment period
You may not be if
Draining fistula count of \> 20 at screening or baseline.
Women who are pregnant (or who are considering pregnancy) or lactating.
Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
History of failure to treatment of inflammatory diseases with JAK inhibitors.
Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.
Participants known to be infected with HIV, Hepatitis B, or Hepatitis C.
Laboratory values outside of the protocol-defined ranges.
Clareo Health | To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
